risks of glp-1 medications linked to major drop in pancreatic, colorectal cancer risk https://www.medicalnewstoday.com/articles/weight-loss-drugs-glp-1-slash-risk -4-types-cancer-50-or-more-study Overdose risks increase as demand

Mayor Michelle Wu celebrated reaching the agreement amid one of the most challenging budget environments in recent years. Together, we are taking steps to responsibly manage rising costs while protecting the health care coverage that our workforce depends on, and the high-quality core City services that our residents deserve, Wu and PEC chair Elissa Cadillic said in a joint statement Wednesday

Why Holistic, Individualized Care Matters Not all patients respond the same way

Much of the focus is on obtaining a new indication for obesity for already FDA-approved diabetes medications such as Tirzepatide (Mounjaro) from Eli Lilly, which was recently approved for obesity under the brand name Zepbound

Because the fraction was incapable of decreasing blood glucose, Kimball and Murlin hypothesized that the hyperglycemic effect resulted from a secreted factor, one that antagonizes insulin's hypoglycemic effect

Doses may be lowered temporarily until symptoms resolve

Typically, they are studied first to treat diabetes, and then go back to the FDA for approval for weight loss